Blocking TGF-β1 protects the peritoneal membrane from dialysate-induced damage

Area of Science:

• Nephrology
• Cell Biology
• Regenerative Medicine

Background:

• Peritoneal dialysis (PD) is essential for kidney failure treatment.
• Mesothelial-to-mesenchymal transition (MMT) contributes to peritoneal membrane dysfunction during PD.
• Transforming growth factor-beta 1 (TGF-β1) is implicated in MMT induction.

Purpose of the Study:

• To investigate the role of TGF-β1 in PD-induced peritoneal damage.
• To evaluate the therapeutic potential of TGF-β1-blocking peptides in a mouse model of PD.

Main Methods:

• A mouse model of PD was established using PD fluid exposure.
• Mesothelial-to-mesenchymal transition (MMT) and fibroblast origins were analyzed using specific markers (cytokeratin, FSP-1, CD31, CD45).
• TGF-β1-blocking peptides were administered, and adenovirus-mediated gene transfer was used to overexpress TGF-β1.

Main Results:

• PD fluid induced peritoneal fibrosis, angiogenesis, functional impairment, and fibroblast accumulation.
• Fibroblasts originated from mesothelial cells (Cyto(+)/FSP-1(+)), endothelial cells (CD31(+)/FSP-1(+)), and bone marrow-derived cells (CD45(+)/FSP-1(+)).
• TGF-β1-blocking peptides ameliorated fibrosis, angiogenesis, and improved peritoneal function, reducing FSP-1(+) cells.
• Overexpression of TGF-β1 exacerbated peritoneal fibrosis and fibroblast accumulation.

Conclusions:

• TGF-β1 is a key mediator of peritoneal deterioration caused by PD fluid.
• TGF-β1-driven MMT plays a significant role in the pathophysiology of peritoneal membrane dysfunction during PD.
• Targeting TGF-β1 offers a potential therapeutic strategy for preserving peritoneal membrane function in PD patients.